'Energy expenditure genes or 'energy absorption genes: A new target for the treatment of obesity and Type II diabetes

Future Medicinal Chemistry

Volumn 2, Issue 12, 2010, Pages 1777-1783

  Braud, Sandrine ^a   Ciufolini, Marco ^b   Harosh, Itzik ^a  

^a ObeTherapy Biotechnology   (France)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; 6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; A 348441; AMG 221; AMYLIN; BVT 83370; CETILISTAT; CIDEA PROTEIN; CT 98014; DRF 415; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOCORTICOID RECEPTOR; GLUCOSE; GRC 9332; GSK 501516; GSK 825964; L 796568; LCQ 908; LEPTIN; LY 377604; MELANOCORTIN; MEMBRANE PROTEIN; MURAGLITAZAR; NAVEGLITAZAR; NN 662; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAFABEGRON; RAGAGLITAZAR; REDONA; REMOGLIFLOZIN ETABONATE; SAXAGLIPTIN; SEROTONIN 2C AGONIST; SEROTONIN 6 RECEPTOR; SIRTUIN 1; SLX 4090; SODIUM; TESAGLITAZAR; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3; UNINDEXED DRUG; VILDAGLIPTIN;

BIOCHEMISTRY; CALORIC RESTRICTION; CLINICAL TRIAL; CONGENITAL ENTEROPEPTIDASE DEFICIENCY; DRUG MECHANISM; DRUG TARGETING; ENERGY ABSORPTION; ENERGY EXPENDITURE; FAILURE TO THRIVE; GENE IDENTIFICATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; HUMAN; INSULIN SENSITIVITY; LIPID ABSORPTION; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVIEW; SATIETY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT INDICATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; ENERGY METABOLISM; ENTEROPEPTIDASE; GENOTYPE; HUMANS; MUTATION; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78650204595     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.263     Document Type: Review

References (36)

1. Rankinen T, Zuberi A, Chagnon YC et al. The human obesity gene map: The 2005 update. Obesity (Silver Spring) 14(4), 529-644 (2006).
2. Reed Dr, Lawler Mp, Tordoff Mg. Reduced body weight is a common effect of gene knockout in mice. BMC Genet. 9, 4 (2008).
3. Tartaglia La, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83(7), 1263-1271 (1995).
4. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505), 425-432 (1994).
5. Friedman Jm. Obesity: Causes and control of excess body fat. Nature 459(7245), 340-342 (2009). n Good question and answer article on obesity.
6. O'Rahilly S. Human genetics illuminates the paths to metabolic disease. Nature 462(7271), 307-314 (2009). n Excellent review article.
7. Horvath Tl. Endocannabinoids and the regulation of body fat: The smoke is clearing. J. Clin. Invest. 112(3), 323-326 (2003).
8. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat. Rev. Drug Discov. 7(12), 961-962 (2008).
9. Boss O, Samec S, Paoloni-Giacobino A et al. Uncoupling protein-3: A new member of the mitochondrial carrier family with tissue-specific expression. FEBS Lett. 408(1), 39-42 (1997).
10. Bouchard C, Perusse L, Chagnon YC, Warden C, Ricquier D. Linkage between markers in the vicinity of the uncoupling protein 2 gene and resting metabolic rate in humans. Hum. Mol. Genet. 6(11), 1887-1889 (1997).
11. Fleury C, Neverova M, Collins S et al. Uncoupling protein-2: A novel gene linked to obesity and hyperinsulinemia. Nat. Genet. 15(3), 269-272 (1997).
12. Kajimura S, Seale P, Kubota K et al. Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-b transcriptional complex. Nature 460(7259), 1154-1158 (2009).
13. Seale P, Bjork B, Yang W et al. Prdm16 controls a brown fat/skeletal muscle switch. Nature 454(7207), 961-967 (2008).
14. Sun C, Zhang F, Ge X et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing ptp1b. Cell Metab. 6(4), 307-319 (2007).
15. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic SIR2-like proteins. Biochem. Biophys. Res. Commun. 273(2), 793-798 (2000).
16. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289(5487), 2126-2128 (2000).
17. Zhou Z, Yon Toh S, Chen Z et al. Cideadeficient mice have lean phenotype and are resistant to obesity. Nat. Genet. 35(1), 49-56 (2003).
18. Fischer J, Koch L, Emmerling C et al. Inactivation of the FTO gene protects from obesity. Nature 458(7240), 894-898 (2009).
19. Olszewski Pk, Fredriksson R, Olszewska Am et al. Hypothalamic FTO is associated with the regulation of energy intake not feeding reward. BMC Neurosci. 10, 129 (2009).
20. Bogardus C. Missing heritability and GWAS utility. Obesity (Silver Spring) 17(2), 209-210 (2009).
21. Coleman Dl. Obesity genes: Beneficial effects in heterozygous mice. Science 203(4381), 663-665 (1979).
22. Neel Jv. Diabetes mellitus: A "thrifty" genotype rendered detrimental by "progress"? Am. J. Hum. Genet. 14, 353-362 (1962).
23. Sharma Am. The thrifty-genotype hypothesis and its implications for the study of complex genetic disorders in man. J. Mol. Med. 76(8), 568-571 (1998). nn Very interesting article on the evolution of metabolic diseases.
24. Kitamoto Y, Yuan X, Wu Q, Mccourt Dw, Sadler Je. Enterokinase, the initiator of intestinal digestion, is a mosaic protease composed of a distinctive assortment of domains. Proc. Natl Acad. Sci. USA 91(16), 7588-7592 (1994). nn Role of enteropeptidase in the digestive system.
25. Mann Ns, Mann Sk. Enterokinase. Proc. Soc. Exp. Biol. Med. 206(2), 114-118 (1994).
26. Fonseca P, Light A. The purification and characterization of bovine enterokinase from membrane fragments in the duodenal mucosal fluid. J. Biol Chem. 258(23), 14516-14520 (1983).
27. Follett Gf, Macdonald Th. Intestinal enterokinase deficiency. Acta Paediatr. Scand. 65(5), 653-655 (1976).
28. Ghishan Fk, Lee Pc, Lebenthal E, Johnson P, Bradley Ca, Greene Hl. Isolated congenital enterokinase deficiency. recent findings and review of the literature. Gastroenterology 85(3), 727-731 (1983).
29. Hadorn B, Tarlow Mj, Lloyd Jk, Wolff Oh. Intestinal enterokinase deficiency. Lancet 1(7599), 812-813 (1969). nn Discuss the importance of enteropeptidase.
30. Haworth Jc, Gourley B, Hadorn B, Sumida C. Malabsorption and growth failure due to intestinal enterokinase deficiency. J. Pediatr. 78(3), 481-490 (1971). nn Discuss the importance of enteropeptidase.
31. Amat L, Martin E, Mateu L, Rubio C, Ballesta A. Malnutrition in congenital deficiency of enterokynase (author's transl). An. Esp. Pediatr. 11(3), 219-226 (1978).
32. Hadorn B, Haworth Jc, Gourley B, Prasad A, Troesch V. Intestinal enterokinase deficiency. Occurrence in two sibs and age dependency of clinical expression. Arch. Dis. Child. 50(4), 277-282 (1975).
33. Polonovski C, Laplane R, Alison F, Navarro J. Trypsinogen pseudo-deficiency caused by congenital enterokinase deficiency. Clinical study. Arch. Fr. Pediatr. 27(7), 677-688 (1970). nn Disucss how congenital enteropeptidase deficiency can be treated.
34. Holzinger A, Maier Em, Buck C et al. Mutations in the proenteropeptidase gene are the molecular cause of congenital enteropeptidase deficiency. Am. J. Hum. Genet. 70(1), 20-25 (2002).
35. Astrup A. The satiating power of protein - a key to obesity prevention? Am. J. Clin. Nutr. 82(1), 1-2 (2005).
36. Westerterp-Plantenga Ms, Nieuwenhuizen A, Tome D, Soenen S, Westerterp Kr. Dietary protein, weight loss, and weight maintenance. Annu. Rev. Nutr. 29, 21-41 (2009).